TLT Anti-Cancer Tech Treats 6th Patient for Bladder Cancer Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers, announced today that the sixth patient in a nine patient Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) was enrolled and treated on February 7, 2018, using the Company’s anti-cancer technology.
The Study is being used to evaluate the Company’s lead PDC drug for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue). The Study also includes an exploratory endpoint of efficacy; however, this will not be a determining factor in the success or failure of the Study.
Three patients have been enrolled and treated at the maximum recommended starting dose of 0.35 mg/cm2 and have successfully achieved the primary, secondary and exploratory endpoints at 90 days post treatment.
Three patients have been enrolled and treated at the therapeutic dose of 0.70 mg/cm2, with patient 4 successfully achieving the primary, secondary and exploratory endpoints at 90 days post treatment.
Patients 5 and 6 will be evaluated for the primary, secondary and exploratory endpoints at 90 days post treatment, in April 2018 and May 2018, respectively.
An additional three patients remain to be enrolled and treated at the therapeutic dose to complete the Study.
The Company plans to commence a multi-center Phase II NMIBC clinical study, in Canada, the United States and internationally with a primary endpoint of efficacy, subject to regulatory approvals.